Please login to the form below

Not currently logged in


This page shows the latest Cotellic news and features for those working in and with pharma, biotech and healthcare.

Another IO knockback as Tecentriq combo fails phase III trial

Another IO knockback as Tecentriq combo fails phase III trial

Roche’s hopes of teaming up checkpoint inhibitor Tecentriq with its targeted cancer drug Cotellic have hit a snag after the first phase III assessment of the duo missed the mark. ... The IMblaze370 trial of PD-L1 inhibitor Tecentriq (atezolizumab) and

Latest news

More from news
Approximately 8 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...